Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David E Joyce

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Current Drug Targets|April 14, 2007
SepsisDavid E Joyce
Current Drug Targets|April 14, 2007
The cancer related thrombotic tendency in sepsisDavid E Joyce
Critical Care Medicine|May 11, 2002
Recombinant human activated protein C attenuates the inflammatory response in endothelium and monocytes by modulating nuclear factor-kappaBDavid E Joyce, Brian W Grinnell
Critical Care Medicine|May 1, 2004
Leukocyte and endothelial cell interactions in sepsis: relevance of the protein C pathwayDavid E Joyce, David R Nelson, Brian W Grinnell
Critical Care (London, England)|May 2, 2003
Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsisGordon R Bernard, William L Macias, David E Joyce, et al.
Blood|July 19, 2003
Survival advantage associated with heterozygous factor V Leiden mutation in patients with severe sepsis and in mouse endotoxemiaBryce A Kerlin, S Betty Yan, Berend H Isermann, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Current Drug Targets|April 14, 2007
SepsisDavid E Joyce
Current Drug Targets|April 14, 2007
The cancer related thrombotic tendency in sepsisDavid E Joyce
Critical Care Medicine|May 11, 2002
Recombinant human activated protein C attenuates the inflammatory response in endothelium and monocytes by modulating nuclear factor-kappaBDavid E Joyce, Brian W Grinnell
Critical Care Medicine|May 1, 2004
Leukocyte and endothelial cell interactions in sepsis: relevance of the protein C pathwayDavid E Joyce, David R Nelson, Brian W Grinnell
Critical Care (London, England)|May 2, 2003
Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsisGordon R Bernard, William L Macias, David E Joyce, et al.
Blood|July 19, 2003
Survival advantage associated with heterozygous factor V Leiden mutation in patients with severe sepsis and in mouse endotoxemiaBryce A Kerlin, S Betty Yan, Berend H Isermann, et al.
Pageof 1